Sanofi-Aventis: net sales up 4.9%, operating income increases 37.4%

By Lisa Kerner

Erie, Pa., May 5 - Sanofi-Aventis reported first-quarter net sales of €7.035 million, a 4.9% increase over the €6.417 million reported for the first-quarter 2005.

Operating income was up for the quarter at €2.951 million, an increase of 37.4% from the first-quarter 2005 operating income of €2.143 million.

Net income for the quarter rose to €2.713 million from €1.415 million year over year.

Sanofi-Aventis reported adjusted earnings per share of €1.62 compared with €1.06 in the 2005 period.

Company highlights include the expected launch in Japan of Plavix in May, the U.S. launch of Apidra insulin analog, the approval of Taxotere in the United States, a 42% increase in net sales of Lantus insulin and settlement of the Apotex patent infringement lawsuit.

Sanofi-Aventis also presented data from various trials at numerous association meetings.

The first-quarter results confirmed Sanofi-Aventis' full-year guidance. The company said it expects a 10% growth in adjusted earnings per share.

Sanofi-Aventis, located in Paris, develops products for the following therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.